2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
10
Neuroendocrine Tumors
6
Gastro-enteropancreatic neuroendocrine tumor
3
Neoplasms by Histologic Type
2
Neoplasms
2
Digestive System Neoplasms
2
Urogenital Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Prostatic Diseases
1
Prostate Cancer Metastatic
1
Pheochromocytoma
1
Paraganglioma
1
Pancreatic Neoplasms
1
Pancreatic Diseases
1
Oligometastatic Prostate Cancer (OMPC)
1
Neuroectodermal Tumors
1
Neoplasms, Nerve Tissue
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Site
1
Neoplasm Metastasis
1
Metastatic Neuroendocrine Prostate Cancer
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Metastatic Castration-Resistant Prostate Cancer
1
Metastatic Castration Resistant Prostate Cancer (mCRPC)
1
Lymphoproliferative Disorders
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Interventions
talazoparib
1
radium Ra 223 dichloride
1
olaparib
1
Pluvicto
1
Lutetium-177
1
Lutetium
1
CX 5461
1
BAY 2315497
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Metastatic Castration Resistant Prostate Cancer (mCRPC)
×
Lutetium-177
×
Clear all
NCT06894511
2026-05-01
PSMAndARPI
Novartis
Phase 2
Active not recruiting
7 enrolled